Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
- Cassiopea, the subsidiary of Cosmo, will be responsible for Centralized Marketing Authorization at European Medicines Agency, while Glenmark will undertake registration of the product in South Africa and in the UK
- Cassiopea will receive an upfront payment of USD 5 million, in addition to double-digit regulatory and sales milestones as well as agreed double-digit royalties on net sales
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (“Glenmark”), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.